×
About 10,810 results

ALLMedicine™ Amyloidosis Center

Research & Reviews  3,920 results

Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Swed...
https://doi.org/10.1080/13506129.2022.2026323
Amyloid : the International Journal of Experimental and C... Mejia Baranda J, Ljungberg J et. al.

Jan 14th, 2022 - Epidemiological data on hereditary transthyretin (ATTRv) amyloidosis from the northernmost region of Sweden (Norrbotten) are sparse. We reviewed the medical records of all incident cases of ATTRv amyloidosis in Norrbotten between 2006 and 2018. Of...

Adequate Antibody Response to COVID-19 Vaccine in Patients with Monoclonal Gammopathies...
https://doi.org/10.1093/labmed/lmab113
Laboratory Medicine; Wu AHB, Wang CC et. al.

Jan 14th, 2022 - Determine the COVID-19 seroconversion rate for patients with multiple myeloma receiving a COVID-19 vaccine. After 45 patients received their second COVID-19 vaccine dose, their serum IgG antibodies were measured: 22 with monoclonal gammopathy (MG)...

A Guide to the Non-Invasive Imaging Assessment of Cardiac Amyloidosis.
https://doi.org/10.1016/j.cjca.2021.12.018
The Canadian Journal of Cardiology; Music S, Szilagyi A et. al.

Jan 13th, 2022 - Cardiac amyloidosis, thought to be rare, is increasingly recognized and benefits from newer therapeutic options. This article provides a practical approach for the clinical cardiologist to the non-invasive assessment of cardiac amyloidosis, from c...

Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response...
https://doi.org/10.1515/cclm-2021-0912
Clinical Chemistry and Laboratory Medicine; Basset M, Milani P et. al.

Jan 13th, 2022 - Quantification of 24 h-proteinuria is the gold standard for diagnosing, staging, and monitoring of patients with renal AL amyloidosis. However, 24 h-urine collection is cumbersome and may result in preanalytical error. In this prospective study, w...

see more →

Guidelines  8 results

JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.
https://doi.org/10.1253/circj.CJ-20-0110
Circulation Journal : Official Journal of the Japanese Ci... Kitaoka H, Izumi C et. al.

Aug 25th, 2020 - JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.|2020|Kitaoka H,Izumi C,Izumiya Y,Inomata T,Ueda M,|classification,diagnosis,drug therapy,epidemiology,therapeutic use,classification,diagnosis,drug therapy,epidemiology,epidemio...

Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement ...
https://doi.org/10.1016/j.cjca.2019.12.025
The Canadian Journal of Cardiology; Chih S, McDonald M et. al.

Mar 9th, 2020 - Significant practice-changing developments have occurred in the care of heart transplantation candidates and recipients over the past decade. This Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement provides evid...

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement...
https://doi.org/10.1016/j.cjca.2019.12.034
The Canadian Journal of Cardiology; Fine NM, Davis MK et. al.

Mar 9th, 2020 - Cardiac amyloidosis is an under-recognized and potentially fatal cause of heart failure and other cardiovascular manifestations. It is caused by deposition of misfolded precursor proteins as fibrillary amyloid deposits in cardiac tissues. The two ...

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgita...
https://doi.org/10.1016/j.cjca.2019.11.036
The Canadian Journal of Cardiology; O'Meara E, McDonald M et. al.

Feb 10th, 2020 - In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provid...

2019 HRS expert consensus statement on evaluation, risk stratification, and management ...
https://doi.org/10.1016/j.hrthm.2019.05.007
Heart Rhythm; Towbin JA, McKenna WJ et. al.

May 13th, 2019 - Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders....

see more →

Drugs  11 results see all →

Clinicaltrials.gov  105 results

Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
https://clinicaltrials.gov/ct2/show/NCT01864018

Jan 13th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose of cyclophosphamide that can be combined with ixazomib citrate (ixazomib) and dexamethasone in patients with previously untreated symptomatic multiple myeloma (MM). (Phase I Cohort A) ...

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
https://clinicaltrials.gov/ct2/show/NCT02939820

Jan 13th, 2022 - Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact t...

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
https://clinicaltrials.gov/ct2/show/NCT04153149

Jan 13th, 2022 - This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
https://clinicaltrials.gov/ct2/show/NCT04899180

Jan 11th, 2022 - Residents of Southeast Minnesota over 75 years of age with an inpatient or outpatient diagnosis of moderate or severe aortic stenosis will be consecutively identified using an automated bi-weekly review of the echo lab calendar (on Mondays and Fri...

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
https://clinicaltrials.gov/ct2/show/NCT05145816

Jan 6th, 2022 - Amyloid light chain amyloidosis (AL amyloidosis, ALA) is a rare plasma cell dyscrasia with an incidence ranging from 9.7-14.0 cases per million person-years. 75% of patients have cardiac involvement at diagnosis as evaluated by plasma cardiac biom...

see more →

News  258 results

Institutional Perspectives in Cancer- Multiple Myeloma: Chaired by Tomer Mark, MD
https://www.onclive.com/view/institutional-perspectives-in-cancer--multiple-myeloma-chaired-by-tomer-mark-md

Dec 19th, 2021 - Institutional Perspectives in Cancer- Multiple Myeloma: Chaired by Tomer Mark, MD The live filming of this virtual event in our IPC series is now on-demand. OncLive is proud to present the State of the Science Summits and a new virtual event, ...

Subcutaneous Daratumumab Plus SOC Maintains Efficacy in Newly Diagnosed AL Amyloidosis
https://www.onclive.com/view/subcutaneous-daratumumab-plus-soc-maintains-efficacy-in-newly-diagnosed-al-amyloidosis

Dec 11th, 2021 - The addition of subcutaneous daratumumab (Darzalex) to standard-of-care bortezomib (Velcade), cyclophosphamide, and dexamethasone (D-VCd) continued to elicit stronger hematologic and organ responses vs VCd alone in patients with newly diagnosed li...

Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma
https://www.onclive.com/view/dr-lentzsch-on-how-patient-age-informs-treatment-decisions-in-multiple-myeloma

Nov 12th, 2021 - Suzanne Lentzsch, MD, professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, College of Physicians and Surgeons of Columbia University, Columbia University Herbert Irving Comprehensive Cancer Center, NewYork-Presbyteri...

Entresto Kickback Probe; Aspirin-Metamizole Deaths; Another Soccer Player Collapses
https://www.medpagetoday.com/cardiology/prevention/95397

Nov 2nd, 2021 - Novartis is cooperating in a Department of Justice investigation on alleged kickbacks for the prescribing of sacubitril/valsartan (Entresto). (FiercePharma) Pricey SGLT-2 inhibitors find their way onto the World Health Organization's updated list ...

When to Treat as Important as Which Drug to Use in WM
https://www.medscape.com/viewarticle/961877

Oct 29th, 2021 - When to initiate treatment is as important as what to use for the treatment of patients newly diagnosed with Waldenstrom macroglobulinemia (WM), a leading expert in the disease emphasizes. "We have to be very careful not to tell patients they have...

see more →

Patient Education  22 results see all →